{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:21:19Z","timestamp":1793917279612,"version":"4.8.0"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>There are no established markers which can be used for surveillance after curative resection in gallbladder carcinoma (GBC). Though carbohydrate antigen 19-9 (CA 19-9) has low specificity as a diagnostic marker, its role as a surveillance marker has not been explored. The aim of this study is to evaluate the predictive ability of CA 19-9 as a surveillance marker to detect recurrences on follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A retrospective analysis of a prospectively maintained database of radically resected GBC who were either on observation or completed adjuvant therapy (chemotherapy or chemoradiation) were followed up 3 monthly with CA 19-9 and ultrasound (US) abdomen for the first 2 years and 6 monthly CA 19-9 and US for further 3 years. Patients with raised CA 19-9 and a recurrent lesion on US abdomen were confirmed with contrast-enhanced computed tomography (CECT) abdomen and fine-needle aspiration cytology (FNAC) of recurrent lesion to establish the diagnosis of recurrence. The performance of CA 19-9 levels (20 and more units\/mL) for prediction of recurrence and its impact on survival was estimated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Out of sixty patients on follow-up, 40% recurred: loco-regional (16.7%) and distant metastases (23.4%). The sensitivity, specificity, positive predictive value, and negative predictive value of CA 19-9 in detecting recurrence were 79.1%, 97.2%, 95%, and 87.5%, respectively. The median disease-free survival was 56 months versus 15 months (P = 0.008, hazard ratio [HR]: 7.4 [1.3\u201340]) and the median overall survival was not reached versus 20 months (P = 0.000, HR: 10.7 [confidence interval 4.2\u201327.3]) for CA 19-9 levels less than and more than 20 ng\/mL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Based on the high positive and negative predictive value in our dataset, CA 19-9 can be used as a surveillance biomarker for follow-up of radically resected GBC. Raised levels of &gt;20 ng\/mL should be correlated with imaging findings and any suspicious lesion should be confirmed for recurrence by FNAC and CECT abdomen. Levels &gt;20 ng\/mL should be taken as a threshold for suspecting recurrence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_702_20","type":"journal-article","created":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T09:51:50Z","timestamp":1626947510000},"page":"273-277","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Raised carbohydrate antigen 19-9 levels detect recurrences and impacts overall and disease-free survival in radically resected gallbladder cancer: A simple surveillance marker?"],"prefix":"10.4103","volume":"19","author":[{"given":"Sushma","family":"Agrawal","sequence":"first","affiliation":[{"name":"Department of Radiotherapy, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajan","family":"Saxena","sequence":"additional","affiliation":[{"name":"Department of Surgical Gastroenterology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,7,23]]},"reference":[{"key":"R1-20241021","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/ijc.21683","article-title":"Gallbladder cancer worldwide: Geographical distribution and risk factors","volume":"118","author":"Randi","year":"2006","journal-title":"Int J Cancer"},{"key":"R2-20241021","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s12029-014-9676-x","article-title":"Outcomes of adjuvant chemo-radiation and predictors of survival after extended cholecystectomy in gall bladder carcinoma: A single institution experience from north India","volume":"46","author":"Agrawal","year":"2015","journal-title":"J Gastrointest Cancer"},{"key":"R3-20241021","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study","volume":"20","author":"Primrose","year":"2019","journal-title":"The Lancet"},{"key":"R4-20241021","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/hpb.12444","article-title":"Gallbladder cancer: Expert consensus statement","volume":"17","author":"Aloia","year":"2015","journal-title":"HPB (Oxford)"},{"key":"R5-20241021","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/MOG.0b013e328325a894","article-title":"Serum and bile biomarkers for cholangiocarcinoma","volume":"25","author":"Alvaro","year":"2009","journal-title":"Curr Opin Gastroenterol"},{"key":"R6-20241021","first-page":"160","article-title":"Diagnostic value of serum CA242, CA 19-9, CA 15-3 and CA 125 in patients with carcinoma of the gallbladder","volume":"27","author":"Shukla","year":"2006","journal-title":"Trop Gastroenterol"},{"key":"R7-20241021","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s12029-011-9288-7","article-title":"Evaluation of CA 242 as a tumor marker in gallbladder cancer","volume":"43","author":"Rana","year":"2012","journal-title":"J Gastrointest Cancer"},{"key":"R8-20241021","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s10620-014-3472-0","article-title":"Serum CYFRA 21-1 in biliary tract cancers: A reliable biomarker for gallbladder carcinoma and intrahepatic cholangiocarcinoma","volume":"60","author":"Huang","year":"2015","journal-title":"Dig Dis Sci"},{"key":"R9-20241021","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s12029-016-9914-5","article-title":"Does CA 19-9 have prognostic relevance in gallbladder carcinoma (GBC)?","volume":"49","author":"Agrawal","year":"2018","journal-title":"J Gastrointest Cancer"},{"key":"R10-20241021","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1245\/s10434-008-9917-y","article-title":"A new scoring system for gallbladder cancer (aiding treatment algorithm): An analysis of 335 patients","volume":"15","author":"Shukla","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"R11-20241021","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1477-2574.2009.00149.x","article-title":"Elevated CA 19-9 portends poor prognosis in patients undergoing resection of biliary malignancies","volume":"12","author":"Hatzaras","year":"2010","journal-title":"HPB (Oxford)"},{"key":"R12-20241021","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.hpb.2017.06.011","article-title":"Elevation of CA19-9 and CEA is associated with a poor prognosis in patients with resectable gallbladder carcinoma","volume":"19","author":"Wen","year":"2017","journal-title":"HPB (Oxford)"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_702_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:38:33Z","timestamp":1787067513000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_702_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,23]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_702_20","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,23]]},"assertion":[{"value":"2020-05-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}